what we do?
Rooted in science
sourced worldwide
LianBio is a Chinese company focused on bringing paradigm-shifting medicines to patients.
Scroll to see more
LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries.
Learn MoreWe are focused on building out a pipeline based on disease relevance to our target markets and the ability to impact patients with transformative mechanisms and precision-based therapeutics. We select programs with a strong scientific basis and clinical data and collaborate with world-class partners across a diverse array of therapeutic areas.
There are over 290 million people in China with cardiovascular disease and more than 100 million with chronic kidney disease. Cardiorenal disease is the leading cause of death in China today.
5.5 people die from cancer every minute in China alone and every year there are more than 4.5 million new cases diagnosed.
November 3, 2020
LianBio Announces Clearance to Initiate the Phase 3 PROOF Trial of Infigratinib in Patients with Locally Advanced or Metastatic Unresectable Cholangiocarcinoma with FGFR2 Gene Fusions in China
October 29, 2020
LianBio Announces $310 Million Crossover Financing
August 11, 2020
MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China
August 11, 2020
BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio
See All
Shanghai Office 9th Floor, Kerry Parkside, 1155 Fangdian Road Unit 901-902 Shanghai, PRC 201204
New Jersey Office 103 Carnegie Center Drive Suite 215 Princeton, NJ 08540
